Assessment of TCF7L2 expression after bariatric surgery

Abstract

Objective To assess the influence of bariatric surgery on transcription factor 7-like 2 ( TCF7L2 ) expression and its association with body mass index (BMI) and Type 2 diabetes mellitus (T2DM). Methods Prospective study performed between 2016 and 2018, where 26 obese patients undergoing bariatric surgery were divided into two subgroups: diabetics and non-diabetics. The RNAs were extracted from peripheral blood samples that were obtained from each patient in two different moments: before surgery and after 12 months of follow-up. The relative expression of TCF7L2 was determined according to the delta-Ct method. Results The linear regression model of BMI x delta-Ct showed a positive correlation (p = 0.037). In the subgroups, an inversely proportional relationship was found between delta-Ct and BMI in the diabetic group and a directly proportional relationship in the non-diabetic group (p>0.05 in both). In the postoperative period, the regression model was similar to the preoperative, except when analyzing the subgroups, where diabetic patients showed a directly proportional relationship (p>0.05). The relative expression of TCF7L2 showed an average of 1.16 ± 0.91, CI-95% 0.79–1.53. There was an increase in relative expression of 48% in the non-diabetic group (p = 0.021), and a decrease of 27% in the T2DM group (p>0.05) in the postoperative. There was a positive correlation between a greater decrease in BMI and increased relative expression (p = 0.027). Conclusion Our results showed that generally, the TCF7L2 expression increase with a decrease in BMI, however, for patients with T2DM, it exhibits an inverse pattern, which is normalized one year after bariatric surgery.

Clinical epigenetics and restoring of metabolic health in severely obese patients undergoing batriatric and metabolic surgery

“…Bariatric and metabolic surgery is an effective therapy in the management of severe obesity and related cardiometabolic risk [9][10][11][12], and, generally, is suggested to patients with a body mass index (BMI) ≥ 40 kg/m [2] who have failed traditional nonsurgical approaches [13][14][15]. Chronologically, we had Roux-en-Y gastric bypass (RYGB), biliopancreatic diversion (BPD), duodenal switch (DS), adjustable gastric banding (AGB), and sleeve gastrectomy (SG).…”

“…Despite the efforts in discovering novel potential non-invasive biomarkers, we are unable to stratify the risk of recovering the weight lost and developing cardiovascular diseases (CVDs) in severely obese patients undergoing weight change [ 1 , 2 ]. Obesity has globally reached epidemic proportions, increasing the risk for type 2 diabetes (T2D) and CVDs as major causes of morbidity and mortality worldwide [ 3 ].…”